hgen_home_2.png

The Cytokine Storm Company

Humanigen, Inc.

Recent News

September 14, 2021
Cameron Durrant, Chairman & CEO, provided a corporate update at the Baird Global Healthcare Conference.

View Presentation

September 14, 2021
Humanigen Announces Participation and Presentation at Multiple Conferences in September

View Press Release

About Us

We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody.

Read More
AdobeStock_203971424.jpeg

"The more original a discovery the more obvious it seems afterwards."

Arthur Koestler